• 2177 Citations
  • 26 h-Index
1986 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 6 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Epirubicin Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
exemestane Medicine & Life Sciences
Anthracyclines Medicine & Life Sciences
Survival Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1986 2019

  • 2177 Citations
  • 26 h-Index
  • 185 Article
  • 8 Review article
  • 1 Comment/debate

Eribulin in the treatment of advanced breast cancer: Real-world scenario from 39 Italian centers - ESEMPiO study

Barni, S., Livraghi, L., Morritti, M., Vici, P., Michelotti, A., Cinieri, S., Fontanella, C., Porcu, L., Del Mastro, L. & Puglisi, F., Jan 1 2019, In : Future Oncology. 15, 1, p. 33-44 12 p.

Research output: Contribution to journalArticle

eribulin
Breast Neoplasms
Safety
Therapeutics
Italy
1 Citations

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

Pizzuti, L., Sergi, D., Sperduti, I., Lauro, L. D., Mazzotta, M., Botti, C., Izzo, F., Marchetti, L., Tomao, S., Marchetti, P., Natoli, C., Grassadonia, A., Gamucci, T., Mentuccia, L., Magnolfi, E., Vaccaro, A., Cassano, A., Rossi, E., Botticelli, A., Sini, V. & 13 othersSarobba, M. G., Fabbri, M. A., Moscetti, L., Astone, A., Michelotti, A., De Angelis, C., Bertolini, I., Angelini, F., Ciliberto, G., Maugeri-Saccà, M., Giordano, A., Barba, M. & Vici, P., Feb 9 2018, (Accepted/In press) In : Cancer Biology and Therapy. p. 1-7 7 p.

Research output: Contribution to journalArticle

Paclitaxel
Body Mass Index
Breast Neoplasms
Disease-Free Survival
Survival

Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)

Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Ancona, C., Airoldi, M., Moretti, G., Ficorella, C., Arcangeli, V., Diodati, L., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L. & 17 othersLa Verde, N., Bianchi, G., Artale, S., Blasi, L., Piezzo, M., Atzori, F., Turletti, A., Benedetto, C., Cursano, M. C., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C. & Clivio, L., Aug 1 2018, In : Oncotarget. 9, 77, p. 34639-34640 2 p.

Research output: Contribution to journalComment/debate

exemestane
Extravehicular Activity
Names
Breast Neoplasms
Everolimus

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Ancona, C., Airoldi, M., Moretti, G., Ficorella, C., Arcangeli, V., Diodati, L., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L. & 19 othersLa Verde, N., Bianchi, G., Artale, S., Blasi, L., Piezzo, M., Atzori, F., Turletti, A., Benedetto, C., Cursano, M. C., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C., Clivio, L., Torri, V. & On behalf of The EVA Study Group, B. O. T. EVA. S. G., Aug 1 2018, In : Oncotarget. 9, 61, p. 31877-31887 11 p.

Research output: Contribution to journalArticle

exemestane
Extravehicular Activity
Breast Neoplasms
Stomatitis
Exanthema
2 Citations
Chemotherapy
Crosstalk
Transducers
Stomach Neoplasms
Wnt Signaling Pathway